Ratings Prestige Consumer Healthcare Inc. Deutsche Boerse AG

Equities

PBV

US74112D1019

Delayed Deutsche Boerse AG Other stock markets 03:06:20 2024-07-01 EDT			5-day change	1st Jan Change
63.5 ^EUR	-2.31%		-1.55%	+14.41%

06-21	DA Davidson Upgrades Prestige Consumer Healthcare to Buy From Neutral, Adjusts Price Target to $93 From $65	MT
05-15	Sector Update: Health Care Stocks Rise Pre-Bell Wednesday	MT

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The group's activity appears highly profitable thanks to its outperforming net margins.
Analysts covering this company mostly recommend stock overweighting or purchase.
Considering the small differences between the analysts' various estimates, the group's business visibility is good.

Weaknesses

As estimated by analysts, this group is among those businesses with the lowest growth prospects.
The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
Revenue estimates are regularly revised downwards for the current and coming years.
For the last few months, analysts have been revising downwards their earnings forecast.
Over the past twelve months, analysts' opinions have been revised negatively.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
PRESTIGE CONSUMER HEALTHCARE INC.	+14.41%	3.44B	-
ELI LILLY AND COMPANY	+55.32%	815B	C+
NOVO NORDISK A/S	+43.19%	641B	B
JOHNSON & JOHNSON	-6.75%	352B	C+
MERCK & CO., INC.	+13.56%	314B	B-
ABBVIE INC.	+10.68%	303B	C+
ASTRAZENECA PLC	+16.19%	242B	B+
ROCHE HOLDING AG	+2.17%	224B	A+
NOVARTIS AG	+13.35%	218B	B-
AMGEN INC.	+8.48%	168B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes